Pasithea Therapeutics Corp (KTTA)

[AJ Freely]

$KTTA - Up 21% Pre-Market/ Current Price $0.47
Announces Intention to Commence a $4m Tender Offer for its Common Stock at Price of $0.70 per Share in Cash

[m0n]

KTTA swinging for the fences here

[The Night Stalker]

as always the gay offerings are everyday common practice with big board biotechs,, always sold at loss on offerings, best to double up on the wedge,.

[The Night Stalker]

as always the gay offerings are everyday common practice with big board biotechs,, always sold at loss on offerings, best to double up on the wedge,.

[Zorro]

Always the waiting game. Patience can pay if you know when to hold. Sometimes even when you get stuck. Love when the dead ones come to life. Lol!

[The Night Stalker]

best to buy them on the wedge with forward milestone events with volume spikes.

im in DRMA averaged down in the wedge pattern. we await for milestone events in coming weeks

[Zorro]

Bottoms in here?

[The Night Stalker]

whats new

[The Night Stalker]

whats new

[PennyStockTrader2]

been accumulating KTTA for months now only to see it go down to the low thirties, so todays news was a nice opportunity to sell a little with a GTC order on the open, you never know when these things can happen. This offer from Lucy Scientific Discovery is laughable and in the very least has brought eyes on KTTA so that its real value can start to be realized.

[Zorro]

*Pasithea Therapeutics Investor Camac Partners Reported Purchase of 155,773 Shares @ Avg Price of $1.21/Share in Form 4 Filing on Thursday
Benzinga

[subslover]

MIAMI BEACH, Fla., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today announced it will present the preclinical proof of concept study results of its tolerizing vaccine program in multiple sclerosis (“MS”) on August 30th at the international conference “From Laboratory to Clinic: Medicine after COVID” held at Trinity College, Oxford University, United Kingdom.



From Laboratory to Clinic is an annual translational research conference established in 1984 that brings together basic scientists, clinicians, and industry researchers to explore how the latest discoveries in immunology and molecular medicine can be applied to improve clinical medicine. During the Symposium, Pasithea’s Chairman, National Academy of Sciences Professor Lawrence Steinman, will be giving the opening keynote lecture. Other speakers will include Dr. Carola Vinuesa, Professor at the Francis Crick Institute in London; Dr. Gali Alter, Professor of medicine at Harvard Medical School; Dr. Jeffrey Ravetch, Professor and head of the Laboratory of Molecular Genetics and Immunology at the Rockefeller University and Dr. Anne Schaefer, Vice-chair of Neuroscience at the Icahn School of Medicine at Mount Sinai.

“We look forward to presenting our data at this important international conference alongside other world recognized leading authorities in immunology and immunotherapy. The study results support the Company’s commitment to the program and move us further along our path to uncover new and effective treatments for neurological disorders,” said Dr. Tiago Reis Marques, Chief Executive Officer of Pasithea.

[$treet $inatra]

great volume day yesterday on that news

[Hercules1]

what does their balance sheet look like?

how much cash do they have?

[subslover]

Pasithea Therapeutics Announces Results of Preclinical Study Demonstrating Tolerizing Vaccine Efficacy in Relapsing-Remitting Model of Multiple Sclerosis
August 11 2022 - 08:00AM
GlobeNewswire Inc.
Alert
Print
Share On Facebook

Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research and development of new and effective treatments for psychiatric and neurological disorders, today announced positive results from a preclinical proof of concept study of PAS002, its tolerizing vaccine program in multiple sclerosis (“MS”).
Earlier this year, a study in Nature, the world's leading science journal, showed that a molecule called GlialCAM found in the brain’s white matter is attacked in MS. GlialCAM shares a component of its protein structure that mimics an identical component of the Epstein Barr Virus (“EBV”) Nuclear Antigen-1, which plays a critical role in triggering MS.

In this proof of concept study, relapsing paralysis was established in a mouse model of relapsing-remitting experimental autoimmune encephalomyelitis (“EAE”), the standard animal model of MS. In three groups, a proprietary DNA cassette was engineered to encode GlialCAM and injected to potentially block acute disease and its relapse. These DNA molecules were designed to protect against paralytic disease by tolerizing the immune system so it would not attack myelin in the brain and spinal cord. The engineered DNA molecule creates tolerance, working like an ‘inverse vaccine’, and was administered intra-muscularly at days 0, 3, 7, 10, and 14. The study had a standard duration of 32 days.

The data showed that the engineered DNA plasmids provide a high level of efficacy in reducing disease severity and incidence of relapse when administered prophylactically in the EAE model, a widely used relapsing-remitting model of MS.

Key findings from the study include:

treatment with a DNA tolerizing ‘inverse vaccine’ delayed the onset of paralysis when compared to vehicle (p<0.001);
a statistically significant reduction in disease severity, when compared to vehicle (p=0.002);
a statistically significant reduction in relapse severity, when compared to vehicle (p<0.001);
treatment with a DNA vaccine prevented disease in approximately 50% of the mice, when compared to vehicle (p=0.004).
The study was conducted at Hooke Laboratories, an independent full-service Contract Research Organization with deep experience in the EAE animal model of MS.

“The results of this study show that this technology has the potential to tolerize to GlialCAM, a myelin molecule that has molecular similarity to the Epstein Barr Virus that triggers MS,” stated Pasithea’s Chairman, National Academy of Sciences Professor Lawrence Steinman, a world recognized leading authority in MS. Prof. Steinman’s research led to the development of the drug Tysabri, which is approved to treat patients with MS and Crohn's disease. “Remarkably, the piece of GlialCAM protein shared between EBV and white matter in the brain is also found in the pox viruses, including monkeypox. Monkeypox is rarely associated with brain inflammation, and this new technology may prove useful as a treatment for brain inflammation caused in certain viral infections.”

Dr. Tiago Reis Marques, Chief Executive Officer of Pasithea, stated, "We’re thrilled with the strong preclinical efficacy data shown in this study. Although early stage, we believe these results demonstrate the promise and validity of our tolerizing approach, which is built on recent data on the biological mechanism linking infection with EBV with the development of MS. We have filed a provisional patent application and we will continue to rapidly pursue the PAS002 drug development program.”

The Company plans to present data from this study, including histology data and plasma inflammatory markers, in future major international conferences, and also to submit full data for peer-review publication.

About Multiple Sclerosis

Multiple Sclerosis (“MS”) is a chronic and potentially disabling autoimmune disease, and the most common neurodegenerative disease of the central nervous system in young adults. The pathological hallmark of MS is the formation of demyelinating lesions in the brain and spinal cord, with the immune system attacking the myelin sheath that normally protects nerve fibers in the brain, spinal cord, and optic nerve. There are now 2.8 million people worldwide who have MS, and every five minutes, someone, somewhere in the world is diagnosed with this disorder. While there is no way to predict with any certainty how an individual’s disease will progress, four basic MS disease courses (also called types or phenotypes) have been defined: clinically isolated syndrome, relapsing remitting, secondary progressive and primary progressive. The most common affecting around 85 per cent of everyone diagnosed with MS is relapsing remitting MS (RRMS). It means that symptoms appear (a relapse), and then fade away, either partially or completely (remitting).

ABOUT PAS002

PAS002 is an engineered DNA plasmid designed to tolerize the immune system to GlialCAM.

About Pasithea Therapeutics Corp.

Pasithea Therapeutics Corporation is a U.S. biotechnology company focused on the discovery, research and development of new and effective treatments for psychiatric and neurological disorders. With an experienced team of experts in the fields of neuroscience and psychopharmacology, Pasithea is developing new molecular entities for the treatment of psychiatric and neurological disorders. Pasithea is also focused on addressing the needs of patients currently suffering with mental illness by providing access to IV ketamine infusions both in clinics and in-home settings.

Forward Looking Statements

This press release contains statements that constitute “forward-looking statements.” Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to the Company on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including, without limitation, those set forth in the Company’s filings with the SEC. Thus, actual results could be materially different. The Company undertakes no obligation to update these statements whether as a result of new information, future events or otherwise, after the date of this release, except as required by law.

Pasithea Therapeutics Corp. Company Contact
Dr. Tiago Reis Marques
Chief Executive Officer

[$treet $inatra]

https://finance.yahoo.com/news/pasithea-therapeutics-announces-financial-business-201500938.html

 
 -- Cash Balance of $52.9 million to fund operations well into 2024 -- 
 -- Initiation of a drug development program in schizophrenia -- 
 -- Initiation of a drug development program in multiple sclerosis -- 
 -- Launched ketamine clinics in the U.K. and U.S. and expanded treatment options --

https://www.globenewswire.com/news-release/2022/03/08/2398871/0/en/Pasithea-Therapeutics-Announces-Collaboration-with-The-Glimpse-Group.html

https://www.benzinga.com/general/biotech/22/02/25388968/exclusive-pasithea-therapeutics-starts-new-multiple-sclerosis-vaccine-development-program

Weekly SAR @ $2.94 https://stockcharts.com/h-sc/ui?s=ktta&p=W&yr=1&mn=3&dy=0&id=p30814693576

NASDAQ 13.2M O/S https://www.otcmarkets.com/stock/KTTA/security

$52M cash on hand versus $25M market cap. Trading below cash value.

CEO exercised options to add 200k shares at $1.44.

Insiders (34.5%) shares are locked up til March. No risk of dumping.

Average share cost from retail is $4.53.

https://www.pasithea.com

[$treet $inatra]

Great to see you here bro! $KTTA oversold and will surely test its all time highs $$$$$$$$


https://stockcharts.com/c-sc/sc?s=KTTA&p=W&yr=2&mn=3&dy=0&i=t6030955154c&r=1646760130996

[ZipCash]

#KTTA ready to break $2.00 plus

New revs coming and its extreme undervalued here

[$treet $inatra]

Monster DD https://www.reddit.com/r/pennystocks/comments/sq0wqi/a_penny_stock_that_is_absurdly_undervalued_enough/

[Aceofspades62]

Beautifull consolidation…adding heavy here. X5 bagger.

[FROZENFLAME]

Adding
$KTTA

[FROZENFLAME]

Huge bid !
$KTTA

[Animas]

Nice red to green day. Gap up in morning.

[Aceofspades62]

Squeeze imminent. Loaded up here.

KTTA

[Blutribe]

OVERSOLD at these levels..I am loading up BIG today!

[RUSTYJ]

guess it not going hold up?any thoughts

[PStockPickz]

I did then shorted 2.25 solid trades so far

[$treet $inatra]

$KTTA +55% enjoy the ride up $$$

[PStockPickz]

Adding some 2.06 looks good if it holds over $2

[PStockPickz]

Back up over $2 let's go!

[$treet $inatra]

bounce time $KTTA $$$ https://finance.yahoo.com/news/pasithea-therapeutics-opens-second-ketamine-130000219.html

https://stockcharts.com/h-sc/ui?s=ktta&p=W&yr=1&mn=3&dy=0&id=p30814693576
https://stockcharts.com/h-sc/ui?s=ktta&p=D&yr=0&mn=3&dy=0&id=p88756283120

[KeepOn]

A little of both. Important to have a bit of a mix.

[reena969]

LOL we are good , I have no problem helping someone. We all have our own ways and decision when it comes to trading and making money. The key is "it your money". and "HOPE is not a Strategy" Find what works best for you. Hope to see you around I'm going to bed I've been up too long, plus I've made my money for the month in 3 days. VIZC on the OTC market, take a look it's being set up, maybe a big run

[alchemytrader]

i already sold 4.05, only missed 4.45 in gains at 8.50 top

[Tiger Money]

I’m not sure I ever called u stupid. I may have been talking in a general sense

[reena969]

No problem....I'm not as "STUPID" as you think. Tiger Money Member Level
Thursday, June 3, 2021 10:26:04 AM
Stupid to sell if u have waited this long from 6. I know the feeling as I sit in the same spot but I didn’t invest a ton here to only make a couple hundred k: I want millions and believe in gs

[Tiger Money]

Awesome, thanks!

[reena969]

I use TD because I'm able to write my own scripts . I paid for Scanz for months until I was able to copy some of the features(that I needed). If your not into putting in the work . Then building a scanner isn't for you. It's a lot of hard work but I prefer that route. It become easy the more you build them. Plus TD is Free. Etrade has one also but it's not as customization as TD .... That's how I was able to quit my job and do this full time. LOVE THIS LIFE....GLTU. BTTX

[Tiger Money]

Yes

[TheFinalCD]

nice bounce so far off 3.70


KTTA

[reena969]

QUIT following people, BUILD A SCANNER/S Find them early ....make MONEY$$$$$$

[da_stock_analyst]

#ktta share offering!!!

[reena969]

Make money, move on anyone get BFRI??? premarket is hot make that Black Friday money.

[reena969]

Nobody trades Premarket???? Money made, Early bird gets the worm. I posted the prices until I sold

[TheFinalCD]

3.50 offering out , through the rundown out the window and scrap the expectations :/

[KOmani]

Today I learned that Premium means under the last traded price.

[Tiger Money]

Well that just smoked me

[TheFinalCD]

$KTTA $30m offering at 3.50/share with warrants at 3.50

$KTTA Pasithea Therapeutics Corp. Announces Pricing of a $30.4 Million Private Placement Priced at a Premium to the Market Under Nasdaq /$3.50

https://ih.advfn.com/stock-market/NASDAQ/pasithea-therapeutics-KTTA/stock-news/86647622/pasithea-therapeutics-corp-announces-pricing-of-a

[reena969]

15 min before PM @ 7.34

[reena969]

PM in 30 min KTTA is @ 8.50